Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 15/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 15/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 15/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22063214 | 0.81 | KDM4E (0.41) | RXRAGRIN1GRIN2BALDH1A1MEN1 | |
| SCHEMBL27045873 | 0.81 | KDM5A (0.35) | RXRAGRIN1GRIN2BNOS3NOS1 | |
| SCHEMBL4569949 | 0.81 | RXRA (0.40) | RXRAGRIN1GRIN2BCHRNA7 | |
| SCHEMBL10175736 | 0.81 | RXRA (0.40) | RXRAGRIN1GRIN2BALDH1A1KMT2A | |
| SCHEMBL4569948 | 0.80 | RXRA (0.39) | RXRAGRIN1GRIN2BALDH1A1CHRNA7 | |
| SCHEMBL11994370 | 0.79 | CYP1A2 (0.46) | RXRAGRIN1GRIN2BALDH1A1NOS3 | |
| SCHEMBL12394763 | 0.78 | HRH4 (0.40) | RXRAGRIN1GRIN2BALDH1A1NOS3 | |
| SCHEMBL29306465 | 0.77 | RXRA (0.33) | RXRAGRIN1GRIN2BNOS3NOS1 | |
| SCHEMBL3507581 | 0.77 | TLR9 (0.38) | RXRAGRIN1GRIN2BALDH1A1CHRNA7 | |
| SCHEMBL21705891 | 0.77 | RXRA (0.35) | RXRAGRIN1GRIN2BALDH1A1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-08-17 | — | — | US | disclosed |
| WO-2023108108-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC (US) | 2023-06-15 | — | — | WO | disclosed |
| WO-2022272060-A1 | EP2 ANTAGONIST COMPOUNDS | RESERVOIR NEUROSCIENCE, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-8658651-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-02-25 | — | — | US | disclosed |
| US-8546404-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME (US) | 2013-10-01 | — | — | US | disclosed |
| US-20120214823-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-08-23 | — | — | US | disclosed |
| US-20120214823-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-08-23 | — | — | US | disclosed |
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | SCHERING CORPORATION | 2011-02-17 | — | — | US | disclosed |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MERCK SHARP & DOHME LLC | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110038876-A1 | HETEROCYCLIC COMPOUNDS AND USE THEREOF AS ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | RXRA 2732/4885GRIN1 2397/4885GRIN2B 3605/4885 |
| US-20090118284-A1 | Novel compounds that are ERK inhibitors | MAPK1, MAPK4, MAPK10 | RXRA 3113/4885GRIN1 2028/4885GRIN2B 3212/4885 |
| US-20230257352-A1 | RAF KINASE INHIBITORS AND METHODS OF USE THEREOF | BRAF, RAF1, ARAF | RXRA 2521/4885GRIN1 4585/4885GRIN2B 4586/4885 |
| US-20120214823-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAPK10 | RXRA 2510/4885GRIN1 1862/4885GRIN2B 3804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.